News
A once-monthly jab cuts body weight by 16% in groundbreaking obesity trial
A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful treatment for obesity. With just a once-monthly shot of 'MariTide,' participants in the study lost as much as 16% of their body weight over the course of a year.
Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...
Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...
Weight loss medications such as Ozempic, Wegovy and Mounjaro have become popular and now there’s a new GLP-1 drug, MariTide, being tested that could be competitive in the market.
Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback